Last updated: 2026-09-06 21:42:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Kodiak Sciences Inc. (KOD) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $35.37, with a market capitalization of $2.22B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.91 to $47.84. This page covers its latest market performance, valuation, price trends and company information.
$2.22B | |
$35.98 | |
$171.21 | |
$1.37 | |
$36.36 | |
571.59K | |
677.32K | |
-- | |
$47.84 | |
$8.91 | |
-- | |
-- |
Kodiak Sciences Inc. (KOD) last closed at $36.36 as of 2026-09-04 23:52:00, unchanged from the previous close of $36.36.
During the latest regular trading session, KOD traded between $1.37 and $171.21, with a volume of 571.59K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Kodiak Sciences Inc. (KOD) moved from $39.12 to $35.37, representing a decline of 9.59% ($3.75).
The stock traded between $35.18 and $40.11 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 590.21 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 68.0%
KOD is currently trading at $35.37, placing it 68.0% of the way from its 52-week low of $8.91 to its 52-week high of $47.84. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 124 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kodiak Sciences Inc. (KOD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.